Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 May 2022 | Story Leonie Bolleurs | Photo Supplied
Prof Hennie van Coller and Prof Hendrik Swart
Prof Hennie van Coller, left, received the the NP van Wyk Louw medal, and Prof Hendrik Swart, right, received the Havenga Prize for Physical Sciences.

The board of the Suid-Afrikaanse Akademie vir Wetenskap en Kuns (SAAWK) recently (22 April) announced the winners of the 2022 prizes. The academy, which was established in 1901, aims to promote the use of Afrikaans in science and the arts.

Havenga Prize for Physical Sciences

Prof Hendrik Swart, NRF B1-rated researcher, SARChI Research Chair in Solid-state Luminescent and Advanced Materials, and Senior Professor in the Department of Physics at the University of the Free State (UFS), received the prestigious Havenga Prize for Physical Sciences.

He says it is an honour to receive this award. “When I look at the list of names that have received the award in the past, I am very humbled and surprised to receive such an award.”

The Havenga Prize, for which candidates are specifically judged on research publications and evidence of their promotion of Afrikaans, has been awarded annually for the past 77 years for original research in the natural sciences or a technical field. 

A collaboration with researchers from the Nelson Mandela University (NMU) on semiconductor materials that improve the efficiency of solar cells, resulted in Prof Japie Engelbrecht (Emeritus Professor, NMU) nominating Prof Swart for this award. He is involved in an NRF collaborative research project with NMU and Linköping University in Sweden.

Prof Swart has played an important role in the acquisition of numerous research devices for analysing the thin layer of phosphor, and the semiconductor devices that can be made from such materials. His research and zeal for his work led to the establishment of the national nano-surface characterisation facility (NNSCF) containing state-of-the-art surface characterisation equipment. 

The PHI Quantes XPS system, for instance, is the first in Africa and one of only 20 in the world. The Quantes XPS system uses X-rays to determine the chemical composition of molecules on the surface of a sample. The system is unique in the sense that it also has an extra X-ray source that can determine the chemical state below the surface, which was not possible in the past. This will help to dictate the position of defects in phosphor materials, which will consequently enable the department to create better phosphor for solid-state lighting as well as solar cell applications.

The most meaningful for him, however, was the production of several well-trained postgraduate students and the generation of high-impact, well-cited scientific publications.

This award, one of several awards he has received during his career, does not signify the end of the road. On the contrary, he is looking forward to improving solar cells by using the phosphor materials they have manufactured, applying it on glass windows doped with phosphors to generate electricity.

NP van Wyk Louw Medal and Alba Bouwer Prize for children's literature

The NP van Wyk Louw Medal was awarded to Prof Hennie van Coller, a researcher who is also affiliated to the UFS. Prof Van Coller, currently an emeritus outstanding professor and research fellow at the university, was a former Head of the UFS Department of Afrikaans and Dutch, German and French, as well as Chairperson of SAAWK. He is known for his impact on the literary world, both locally and internationally, through the quality of his scientific articles and books. 

According to SAAWK, the body awards the NP van Wyk Louw Medal for a person’s creative contributions to the exploitation, organisation, and continuous development of a section of the humanities, significantly contributing to the advancement of the humanities.

Jaco Jacobs, the children’s author of more than 170 books who recently presented the 35th DF Malherbe Memorial Lecture at the UFS, was also awarded for his work. Jacobs, also a UFS alumnus, received the Alba Bouwer Prize for children's literature. The prize, which is awarded every three years, was presented to Jacobs for the book Die boekwinkel tussen die wolke, written during the COVID-19 lockdown period. 

SAAWK will present the awards later this year during two virtual award ceremonies in July. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept